Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
64 巻, 22 号
選択された号の論文の28件中1~28を表示しています
ORIGINAL ARTICLES
  • Kiu Tanaka, Masatoshi Minamisawa, Ayako Okada, Daisuke Sunohara, Yoshi ...
    2025 年64 巻22 号 p. 3178-3187
    発行日: 2025/11/15
    公開日: 2025/11/15
    [早期公開] 公開日: 2025/05/08
    ジャーナル オープンアクセス

    Objective The HELT-E2S2 score is a novel risk assessment tool for ischemic stroke in patients with atrial fibrillation. We explored the prognostic impact of the HELT-E2S2 score on cardiovascular outcomes in patients with heart failure (HF), beyond its original scope.

    Methods We enrolled 997 patients hospitalized for acute decompensated HF (ADHF) (median age, 81 years; 44.3% female) from the Clue of Risk Stratification in the Elderly Patients with Heart Failure (CURE-HF) registry. We evaluated the relationship between the HELT-E2S2 score and all-cause death over a median follow-up of 2.7 years.

    Results The patients were categorized into four quartiles based on the HELT-E2S2 score: score 0 or 1 (group 1, n=234), score 2 (group 2, n=244), score 3 (group 3, n=255), and score ≥4 (group 4, n=264). Atrial fibrillation was present in 592 (59.4%) patients (paroxysmal, 15.0%; persistent, 44.3%). All-cause death was observed in 384 patients (14.7 per 100 patient-years). A Kaplan-Meier analysis showed that the higher score group was associated with an increased risk of all-cause death (log-rank p<0.001). After multivariable adjustment, the higher score groups had an elevated risk of all-cause death compared to group 1 [group 2; hazard ratio (HR): 1.56; 95% confidence interval (CI): 1.03-2.37; p=0.037, group 3; HR: 2.74; 95% CI: 1.85-4.07; p<0.001, group 4; HR: 3.32; 95% CI: 2.34-4.94; p<0.001].

    Conclusion Higher HELT-E2S2 scores were associated with a higher risk of all-cause death in patients with ADHF.

  • Kosei Okamoto, Fumitaka Tanaka, Seiya Noda, Motoyuki Nakamura, Kozo Ta ...
    2025 年64 巻22 号 p. 3188-3196
    発行日: 2025/11/15
    公開日: 2025/11/15
    [早期公開] 公開日: 2025/05/29
    ジャーナル オープンアクセス

    Objective Malnutrition is a common problem among patients with chronic kidney disease (CKD). It is unknown whether serum cholinesterase, an indicator of the nutritional status, has a significant value as a prognostic marker in patients with non-dialysis-dependent CKD, including those in the early phase.

    Methods A total of 4,505 middle-aged and older people with stage 1-4 CKD who were free from cardiovascular events (mean age: 67.2 years) were followed up for an average of 10.3±2.4 years. We investigated the association of serum cholinesterase levels with all-cause mortality using multivariable regression analyses and restricted cubic spline analyses.

    Results A total of 840 (18.6%) participants died. The multivariable-adjusted hazard ratios (HRs) for all-cause mortality were significantly increased in patients with serum cholinesterase in the first and second quartiles compared to patients in the highest quartile in the entire cohort [HR=1.61, 95% confidence interval (CI), 1.28-2.03; HR=1.37, 95% CI, 1.09-1.71, respectively]. A reverse-J relationship between the serum cholinesterase levels and all-cause mortality was found in the entire cohort as well as in patients grouped according to stage 1-2 CKD and stage 3-4 CKD (all p for nonlinearity: <0.030). The inclusion of the serum cholinesterase level improved the accuracy of reclassification in a conventional prediction model for 10-year all-cause mortality (continuous net reclassification improvement=0.167, p<0.001; integrated discrimination improvement=0.005, p<0.001).

    Conclusion In middle-aged and older people with stage 1-4 CKD, the serum cholinesterase level had significant value in predicting all-cause mortality and added prognostic information to conventional risk assessments.

  • Nobuyasu Awano, Taisuke Jo, Takehiro Izumo, Hirokazu Urushiyama, Hirok ...
    2025 年64 巻22 号 p. 3197-3202
    発行日: 2025/11/15
    公開日: 2025/11/15
    [早期公開] 公開日: 2025/05/08
    ジャーナル オープンアクセス
    電子付録

    Objective The number of patients using direct oral anticoagulants (DOACs) has recently increased. However, the association between DOAC use and bronchoscopy (BS) safety has not been elucidated. This study examined the association between BS and DOAC use and safety.

    Methods Using data from the Japanese Diagnosis Procedure Combination database from July 1, 2010, to March 31, 2022, patients taking DOACs who underwent BS (n=603, DOAC group) and those who did not (n=187,827, non-DOAC group) were identified. Then, 1:4 matched-pair cohort analyses were performed based on the institution, sex, age, and treatment year. The primary outcome was all-cause in-hospital mortality. The secondary outcomes were 28-day mortality, mechanical ventilation use, pneumothorax, bleeding, and thromboembolism after BS.

    Results A total of 603 and 2,320 patients taking and not taking DOAC, respectively, were identified via matching. The all-cause in-hospital mortality rates in the DOAC and non-DOAC groups were 12.1% and 5.8%, respectively. In a multivariable logistic regression analysis, the DOAC group had a significantly higher all-cause in-hospital mortality rate than the non-DOAC group (odds ratio = 2.84, 95% confidence interval = 1.77-4.55). Secondary and composite outcomes (mechanical ventilation, pneumothorax, bleeding, and thromboembolism after BS combined) were more frequent in the DOAC group than in the non-DOAC group.

    Conclusion DOACs were associated with mortality and complications in patients undergoing BS. Further studies comparing BS outcomes between patients with and without DOAC treatment are necessary.

  • Tomoyuki Saga, Michiyo Kanagawa, Tomoya Harada, Toshimichi Ishihara
    2025 年64 巻22 号 p. 3203-3213
    発行日: 2025/11/15
    公開日: 2025/11/15
    [早期公開] 公開日: 2025/05/29
    ジャーナル オープンアクセス

    Objective The immature platelet fraction (IPF) reflects the thrombopoietic activity and it is useful for diagnosing thrombocytopenic disorders. TAFRO syndrome is a fatal disease that requires an accurate diagnosis and urgent treatment. Thrombocytopenia is essential for the diagnosis of TAFRO syndrome; however, it can develop later during the course of the disease. The significance of IPF and the frequency of late-onset thrombocytopenia in TAFRO syndrome remains unclear. This study investigated the relationship between the platelet count and IPF as well as the absence of thrombocytopenia upon admission for TAFRO syndrome.

    Methods We herein present the follow-up of our previously reported case and two other cases of TAFRO syndrome with serial IPF measurements performed at our hospital. We reviewed cases published between 2010 and 2024 from the PubMed database. This study included patients diagnosed according to the criteria for TAFRO syndrome proposed in 2019.

    Results Of the 167 eligible patients, pretreatment IPF was measured in 11, including four with serial measurements. In these 11 patients, the median pretreatment IPF was 18.2% (range 9.8-32.0) and that of the corresponding platelet count was 67,000/μL (range 8,000-179,000). Pretreatment IPF was elevated (≥ 10%) in 10 patients (90.9%), including four without thrombocytopenia. There was no significant correlation between the platelet count and IPF. Thirty-four of 167 patients (20.3%) did not have thrombocytopenia upon admission.

    Conclusion The pretreatment IPF levels were elevated in most of the patients. Late-onset thrombocytopenia was common. An increased pretreatment IPF level may be a diagnostic indicator of TAFRO syndrome, particularly in patients without thrombocytopenia on admission.

  • Hideaki Tsuji, Yuki Aitani, Yudai Koshida, Keisuke Hirobe, Kazuma Yosh ...
    2025 年64 巻22 号 p. 3214-3225
    発行日: 2025/11/15
    公開日: 2025/11/15
    [早期公開] 公開日: 2025/05/15
    ジャーナル オープンアクセス
    電子付録

    Objective To analyze the influence of age of the onset on myositis organ damage and to identify the factors influencing myositis organ damage, as clinical manifestations of myopathies differ by the age of onset and the background of patients.

    Methods Factors influencing organ damage [the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index (SDI)] were identified using the Japanese multicenter myositis registry (MYKO, n=220). Factors influencing organ damage were identified using a multivariate analysis. SDI was compared among juvenile-onset (<20 years old), adolescent-onset (20-64 years), and elderly-onset (>64 years) groups.

    Results There was a correlation between the age at onset and the SDI score (Spearman's rank correlation coefficient ρ=0.28). Elderly patients exhibited more widespread organ damage, including neuropsychiatric, renal, pulmonary, cardiovascular, peripheral vascular, gastrointestinal, skin, and diabetes, whereas juvenile-onset patients exhibited musculoskeletal damage. Adolescent-onset patients had the lowest incidence of ocular and malignant damage. A regression analysis revealed that an older onset age (coefficient, β=0.03), longer disease duration (β=0.05), and total dose of glucocorticoid (β=3.35×10-5) influenced SDI. After adjusting for disease duration, the influences of anti-melanoma differentiation-associated gene 5 (MDA5) [hazard ratio (95% confidence interval), 4.47 (2.17-9.21)] on pulmonary fibrosis and a history of steroid pulse [2.16 (1.16-4.05)] on muscle atrophy or weakness were shown.

    Conclusion There were associations between the age of onset and autoantibodies with myositis organ damage. Musculoskeletal damage was greater in patients with a juvenile onset. An older age of onset is associated with severe organ damage. These findings highlight the importance of considering the age of onset and autoantibodies for assessing the prognosis and developing treatment plans for myopathies.

CASE REPORTS
PICTURES IN CLINICAL MEDICINE
LETTERS TO THE EDITOR
feedback
Top